Barbados vs Mauritania: Access to anti-retroviral drugs, female
Barbados
67.0%
in 2024
Mauritania
68.0%
in 2024
Barbados rank
88th
Mauritania rank
86th
Access to anti-retroviral drugs, female over time
- Barbados
- Mauritania
How they compare
Mauritania currently reports 68.0% against 67.0% in Barbados, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Mauritania ahead.
Barbados ranks 88th and Mauritania ranks 86th of 141 countries.
Barbados has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Barbados | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 20.4% | 5.6% | 14.8% | Barbados |
| 2010s | 51.6% | 35.7% | 15.9% | Barbados |
| 2020s | 65.8% | 60.4% | 5.4% | Barbados |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Barbados or Mauritania?
- Mauritania, at 68.0% against 67.0% in Barbados as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Barbados and Mauritania?
- 1.0%, with Mauritania ahead.
- How many years of comparable data are there for Barbados and Mauritania?
- 25 years are reported by both, from 2000 to 2024.
- How do Barbados and Mauritania rank globally for access to anti-retroviral drugs, female?
- Barbados ranks 88th and Mauritania ranks 86th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.